Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
536. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
View |
537. |
ECCT/23/07/05 | Sabin A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults |
Principal Investigator(s) 1. Prof. Videlis Nduba Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya |
View |
538. |
ECCT/25/10/01 | H06_04TP A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years after vaccination in African children. |
Principal Investigator(s) 1. Deborah Chepngeno Langat Site(s) in Kenya KEMRI CRC WRP KERICHO |
View |
539. |
ECCT/17/08/03 | Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria. |
Principal Investigator(s) 1. Grace Kiringa Kaguthi Site(s) in Kenya KEMRI Siaya |
View |
540. |
ECCT/21/06/03 | VAT00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. PROF.ELIZABETH ANNE BUKUSI 2. MARICIANAH A ONONO Site(s) in Kenya 1. Kenya Medical Research Institute (KEMRI) Center for Microbiology Research - Research Care and Training Program (KEMRI CMRRCTP) (Kisumu county) 2. KEMRI CCRButere County Hospital Site (Kakamega county) 3. Aga Khan University Hospital (Nairobi City county) 4. Kenya Medical Research Institute CGHR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI/CCR Partners in Health R&D (PHRD (Kiambu county) 7. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 8. Ganjoni Clinic (Mombasa county) 9. KEMRI-UAMRD-A/K, Kombewa Clinical Research Cente (Kisumu county) 10. KEMRI/Walter Reed Project Research Center (Kericho county) |
View |